Division of Infectious Diseases, University of Texas Medical Branch, Galveston, Texas, USA.
Sede Cusco - Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Cusco, Peru.
Curr Opin Infect Dis. 2018 Oct;31(5):409-414. doi: 10.1097/QCO.0000000000000482.
This review aims at describing the latest research in Fasciola epidemiology, diagnosis, treatment, and control in endemic countries.
The geographic distribution and range of reservoirs for Fasciola hepatica continues to expand. The impact of fascioliasis goes beyond human disease to affect food security and income in developed and developing countries. Promising serologic and molecular methods to diagnose fascioliasis have been described, but are not widely available. Triclabendazole remains the only highly active medication to treat human and livestock infected with juvenile and adult forms of Fasciola spp. Efforts to control fascioliasis may be hindered by the emergence of resistance to triclabendazole among livestock and subsequently in humans.
Increased awareness and surveillance are likely to uncover the real distribution and burden of fascioliasis in human. Research into new drugs or adjuvants to tackle the emerging resistance to triclabendazole is imperative to treat and control Fasciola infection.
本综述旨在描述流行地区华支睾吸虫病的最新流行病学、诊断、治疗和控制研究。
肝片形吸虫的地理分布和宿主范围不断扩大。华支睾吸虫病的影响不仅限于人类疾病，还会影响发达国家和发展中国家的粮食安全和收入。已经描述了有前途的血清学和分子方法来诊断片形吸虫病，但尚未广泛应用。三氯苯达唑仍然是唯一高度有效的药物，可治疗感染了华支睾吸虫幼体和成虫的人类和牲畜。控制华支睾吸虫病的努力可能会因牲畜对华支睾吸虫病的耐药性以及随后在人类中出现耐药性而受到阻碍。
提高认识和监测可能会发现人类华支睾吸虫病的真实分布和负担。研究新的药物或佐剂来解决三氯苯达唑的耐药性问题，对于治疗和控制华支睾吸虫感染至关重要。
